Scientific advisors

AlzeCure Pharma has a network of leading scientific advisors within neurodegenerative disorders. They assist AlzeCure with their specialist knowledge and give input to both preclinical and clinical studies.

Professor Bengt Winblad
Professor Bengt Winblad
Karolinska Institutet, Stockholm, Sweden

Professor at Karolinska Institutet in Stockholm and one of the world’s most cited researchers in neurodegenerative diseases.
In 2016, Professor Winblad was the recipient of the Life-Time Achievement Award from the US-based Alzheimer’s Association for his invaluable contributions to Alzheimer’s research. Professor Winblad is also the recipient of the Swedish Brain Foundation’sJubilee Award.

Professor Henrik Zetterberg
Professor Henrik Zetterberg
Gothenburg University and University College London, UK

UK Professor of neurochemistry, Chief physician at Sahlgrenska University Hospital and Professor at University College London (UCL). Professor Zetterberg is also chair of the Swedish Alzheimer’s Foundation Scientific Council and is a leading global authority in the field of biomarkers related to neurodegenerative diseases.

Professor Peter Snyder
Professor Peter Snyder
University of Rhode Island, USA

Vice President of Research and Economic Development and Professor of Biomedical Sciences at the University of Rhode Island, Kingston, RI. Professor Snyder has extensive experience with leading positions in the field of Neuroscience, including at Pfizer, where he led the development of new compounds for the treatment of schizophrenia and Alzheimer’s disease. He is also Senior Associate Editor for Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

Associate Professor John Harrison
Associate Professor John Harrison
Alzheimer Center, VUmc, Amsterdam, The Netherlands

Professor at Alzheimer Center VU Medical Center in Amsterdam and visiting professor at the Institute of Psychiatry,
Psychology & Neuroscience at King’s College London. Dr.Harrison has more than 20 years of experience in successfully integrating cognitive testing into drug development programs. He has worked with more than 40 drug development organizations in recent years, including 8 of the current Fortune top 10 pharmaceutical companies.

Dr. Rolf Karlsten
Dr. Rolf Karlsten
Academic Hospital, Uppsala, Sweden

University Hospital, Uppsala, Sweden MD, specialist in anesthesiology and pain management. PhD in pain research 1994. Previously worked as head of Medical Science with a main focus on pain projects in major pharmaceutical companies. Currently head of the Interdisciplinary Pain Center at Uppsala University Hospital, which covers all types of acute and chronic pain conditions.

Professor Sven Ove Ögren
Professor Sven Ove Ögren
Karolinska Institutet, Stockholm, Sweden

Karolinska Institutet, Stockholm, Sweden Professor at Karolinska Institutet, Sweden. Recognized scientist in the field of Neuropsychology with extensive experience in drug development – project leader for two drug products developed from concept to market in the CNS area. More than 400 publications in the field of neuropsychiatry and cognition.